8-K: INmune Bio Announces Positive Phase 2 Alzheimer's Trial Update and Third Quarter 2024 Financial Results

INmune Bio reports completion of enrollment for its Phase 2 Alzheimer's trial, positive interim analysis of a novel cognitive measure, and third quarter 2024 financial results.

Summary

• INmune Bio has completed enrollment for its Phase 2 Alzheimer's Disease trial, with a potential for modest over-enrollment.
• Interim analysis of the Alzheimer's trial showed a strong correlation between the new cognitive measure EMACC and the established CDR-SB scale.
• The company's INKmune platform demonstrated safety and increased NK-cell activity in a Phase I/II trial for metastatic castration-resistant prostate cancer.
• A new formulation of INKmune has been developed to support higher trial doses and scalable manufacturing.
• INmune Bio secured approximately $13.0 million in gross proceeds through securities purchase agreements.
• The company reported a net loss of approximately $12.1 million for the third quarter of 2024, compared to a loss of $8.6 million in the same quarter of 2023.
• Research and development expenses increased to approximately $10.1 million for the quarter, up from $6.0 million in the prior year.
• As of September 30, 2024, the company had approximately $33.6 million in cash and cash equivalents.
• Top-line data from the Phase 2 Alzheimer's trial is expected in the second quarter of 2025.

Sentiment

Score: 7

Explanation: The document presents a mix of positive clinical trial updates and financial results. The positive data from the Alzheimer's and prostate cancer trials, along with the capital raise, are encouraging. However, the increased net loss and R&D expenses temper the overall sentiment.

Positives

• The completion of enrollment in the Phase 2 Alzheimer's trial is a significant milestone.
• The strong correlation between EMACC and CDR-SB suggests EMACC is a reliable and sensitive cognitive measure.
• The safety and increased NK-cell activity observed with INKmune in the mCRPC trial are promising.
• The new formulation of INKmune and expansion of bioreactor capacity support future scalability.
• The successful capital raise of $13.0 million strengthens the company's financial position.
• The addition to the Russell 3000 Index increases the company's visibility.
• The research and development rebate from Australia provides additional funding.

Negatives

• The company reported a net loss of approximately $12.1 million for the third quarter of 2024, which is higher than the $8.6 million loss in the same quarter of 2023.
• Research and development expenses increased significantly to approximately $10.1 million for the quarter, up from $6.0 million in the prior year.
• The company's cash and cash equivalents decreased to approximately $33.6 million as of September 30, 2024, from $35.8 million at the end of 2023.

Risks

• Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved.
• The company's ability to produce more drug for clinical trials is a risk.
• The availability of substantial additional funding for the company to continue its operations is a risk.
• The company's business, research, product development, regulatory approval, marketing and distribution plans and strategies are subject to risks and uncertainties.
• There is no guarantee that INB03, XPro1595 (XPro), and INKmune will be approved by the FDA or any regulatory body.

Future Outlook

Top-line data from the Phase 2 Alzheimer's trial is expected in the second quarter of 2025. A Phase II trial of XPro in patients with Treatment-Resistant Depression is expected to be initiated in the second half of 2024. Enrollment in the Phase I portion of the INKmune mCRPC trial is expected to be completed by year-end, with Phase II enrollment expected to complete in Q2 2025.

Management Comments

• The company is focused on developing treatments that harness the patients innate immune system to fight disease.
• The company is pleased with the progress of its clinical trials and the development of its product platforms.

Industry Context

This announcement reflects the ongoing efforts in the biotechnology industry to develop novel treatments for neurodegenerative diseases like Alzheimer's and cancer, with a focus on harnessing the immune system. The use of biomarkers and novel cognitive measures is also a growing trend in clinical trials.

Comparison to Industry Standards

• The correlation of 0.93 between EMACC measurements is very high, suggesting a robust and reliable measure, which is comparable to or better than many established cognitive tests used in Alzheimer's trials.
• The effect size of 0.87 for EMACC in differentiating between prodromal and mild dementia is considered large, indicating a strong ability to distinguish between disease stages, which is a key requirement for effective clinical trial endpoints.
• The safety profile of INKmune, with over 30 infusions given without significant adverse events, is a positive sign compared to other cell-based therapies that often require pre-medication or cytokine support.
• The increase in NK cell activity and the transient decrease in PSA in the mCRPC trial are encouraging, although further data is needed to compare to other treatments in this space.
• The company's cash position of $33.6 million is relatively modest for a clinical-stage biotech company, and the increased R&D spending is typical for companies advancing multiple clinical programs.

Stakeholder Impact

• Shareholders may react positively to the clinical trial progress and capital raise.
• Employees may be encouraged by the company's progress and financial stability.
• Patients may benefit from the potential new treatments being developed.
• Creditors may be reassured by the company's ability to raise capital.

Next Steps

• The company will continue to enroll patients in the Phase II portion of the INKmune mCRPC trial.
• Top-line data from the Phase 2 Alzheimer's trial is expected in the second quarter of 2025.
• A Phase II trial of XPro in patients with Treatment-Resistant Depression is expected to be initiated in the second half of 2024.
• The company will provide periodic updates on the immunologic and therapeutic response to INKmune as data becomes available.

Key Dates

Keywords

Alzheimer's Disease, INKmune, XPro, Neuroinflammation, Natural Killer Cells, Prostate Cancer, Clinical Trials, Immunotherapy, DN-TNF, Biotechnology